Biomarking the Difference: How Second-Generation Therapies

Overview
Clinical trials have demonstrated the durability of second-generation treatments for retinal disease. How can these gains be realized in everyday practice and what biomarkers of disease activity should specialists be assessing? Watch these short but informative videos to learn how our faculty are leveraging these new therapies to achieve the best possible vision outcomes for their patients.
Target Audience
This certified continuing education (CME) activity is designed for ophthalmologists involved in the management of patients with retinal diseases.
Grantor Statement
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Learning Objectives
Upon completion of this activity, the participant should be able to: 
- Evaluate how imaging biomarkers reflect disease severity and could inform personalized treatment strategies
- Analyze the clinical significance of imaging biomarkers in the context of anatomical and visual outcomes for patients treated with second-generation therapies
- Interpret the impact of early fluid resolution on long-term treatment durability and patient outcomes
- Apply clinical trial findings to optimize treatment intervals in real-world practice
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education 

Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty
Justis P. Ehlers, MD, FASRS
Cole Eye Institute
Cleveland Clinic
Cleveland, OH
Roger A. Goldberg, MD, MBA
Partner, Bay Area Retina Associates
Walnut Creek, CA
Faculty, CPMC Ophthalmology Residency
San Francisco, CA
Jennifer, I. Lim, MD, FASRS, FARVO
Marion H. Schenk Chair in Ophthalmology
Vice-Chair for Diversity, Equity & Inclusion
Director of the Retina Service
UIC Distinguished Professor of Ophthalmology
University of Illinois at Chicago
Chicago, IL
Ehsan Rahimy, MD
Palo Alto Medical Foundation
Stanford University School of Medicine
Palo Alto, CA
Disclosure of Relevant Financial Relationships
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Justis P. Ehlers, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biotechnologies, Alcon, Alexion, Allegro Ophthalmics, Allergan, Apellis Pharmaceuticals, Bayer, Beyeonics, Boehringer Ingelheim, BVI, Carl Zeiss Meditec, Exegenesis Bio, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Leica Microsystems/Bioptigen, Novartis, Ophthalytics, Perceive Bio, Regeneron, Regenxbio, Roche, and Stealth BioTherapeutics. Grant/Research Support: Adverum Biotechnologies, Aerpio, Alcon, Alexion, Allergan, Beyeonics, Boehringer Ingelheim, Carl Zeiss Meditec, Genentech, Iveric Bio, Novartis, Oxurion/Thrombogenics, Perceive Bio, Regeneron, Roche, and Stealth BioTherapeutics.
Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Emmetrope Ophthalmics. Consultant: AbbVie, Adverum Biotechnologies, Alimera Sciences, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, EyePoint Pharmaceuticals, Genentech, Janssen, Neurotech Pharmaceuticals/LMRI, Ocular Therapeutix, Opthea, Orasis Pharmaceuticals, Regeneron, and Stealth BioTherapeutics. Grant/Research Support: 4DMT, AbbVie, AffaMed Therapeutics, Alexion, Annexon Biosciences, Apellis Pharmaceuticals, Avirmax, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Cognition Therapeutics, EyePoint Pharmaceuticals, Genentech, Janssen, Neurotech Pharmaceuticals/LMRI, Novo Nordisk, Ocular Therapeutix, Regeneron, Stealth BioTherapeutics, and Unity Biotechnology. Speaker’s Bureau: Apellis Pharmaceuticals and Genentech.
Jennifer, I. Lim, MD, FASRS, FARVO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Astellas/Iveric Bio, Aura Biosciences, Cognition, EyePoint Pharmaceuticals, Eyenuk, Genentech, Luxa, Opthea, Regeneron, Unity, and Viridian. Advisory Board: Alcon, Alimera, Apellis Pharmaceuticals, Bausch + Lomb, and Ocular Therapeutix. Grant Support: Aldeyra, Genentech, Graybug, Janssen/ Johnson & Johnson, Kyoto Drug/Discovery, NGM, Ocular Therapeutix, Regeneron, Regenxbio, Spring Vision, and Stealth.
Ehsan Rahimy, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Apellis Pharmaceuticals, Astellas/Iveric Bio, EyePoint, Genentech, Harrow, Regeneron, and Zeiss. Speaker’s Bureau: AbbVie/Allergan, Apellis Pharmaceuticals, Genentech, and Regeneron.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. 
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 06/02/2025
Expiration Date: 06/02/2026